Investing.com - Regulus (NASDAQ:RGLS) Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Regulus Therapeutics announced earnings per share of $-0.5000 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.4950 on revenue of $0.00.
Regulus Therapeutics shares are down 53.92% from the beginning of the year, still down 62.81% from its 52 week high of $4.37 set on November 11, 2021.
Regulus Therapeutics follows other major Healthcare sector earnings this month
Regulus Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar